DDInter1625 DDInter1003
Rubella virus vaccine is a live attenuated virus vaccine for active immunization against rubella (German measles) that is subcutaneously administered. It is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a common childhood disease, caused by rubella virus (togavirus).
Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis. Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons for the protein backbone of the molecule. It is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Ixekizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Ixekizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lidocaine
Ixekizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis B Vaccine (Recombinant)
Ixekizumab {u} may lead to a major life threatening interaction when taken with {v} Etanercept
Ixekizumab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Ixekizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine
Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Ixekizumab may lead to a major life threatening interaction when taken with Etanercept
Ixekizumab may lead to a major life threatening interaction when taken with Upadacitinib